Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sequential chemoimmunotherapy for metastatic melanoma.

J M Richards1

  • 1Section of Hematology/Oncology, University of Chicago, IL 60637.

Seminars in Oncology
|October 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.

British journal of cancer·2013
Same author

Keratoconjunctivitis sicca; a sequela of purulent erythema multiforme exudativum (Stevens-Johnson disease); report of a case.

Archives of ophthalmology (Chicago, Ill. : 1929)·2010
Same author

Keratoconjunctivitis sicca; a sequela to purulent erythema exudativum multiforme (Stevens-Johnson's disease).

American journal of ophthalmology·2010
Same author

Physicians on Hospital Boards.

Canadian Medical Association journal·2010
Same author

Refining the application of direct embryogenesis in sugarcane: Effect of the developmental phase of leaf disc explants and the timing of DNA transfer on transformation efficiency.

Plant cell reports·2006
Same author

(2,2':6',2"-Terpyridine)platinum(II) complexes are irreversible inhibitors of Trypanosoma cruzi trypanothione reductase but not of human glutathione reductase.

Journal of medicinal chemistry·2000
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

This study investigated a novel chemoimmunotherapy regimen for metastatic melanoma, achieving a 24% complete response rate and 36% partial response rate in 25 patients. The treatment shows promise for advanced melanoma patients.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Metastatic melanoma presents a significant therapeutic challenge.
  • Novel treatment strategies are crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate a sequential chemoimmunotherapy regimen for metastatic melanoma.
  • To determine the response rates and duration of treatment.

Main Methods:

  • A regimen including carmustine, dacarbazine, cisplatin, interleukin-2, alpha-interferon, and tamoxifen was administered sequentially.
  • Thirty-nine patients were enrolled, with 25 completing at least one cycle and evaluated for response.

Main Results:

  • Complete response (CR) was observed in 6 of 25 patients (24%).
  • Partial response (PR) was observed in 9 of 25 patients (36%).

Related Experiment Videos

  • Stable disease (SD) was noted in 8 of 25 patients (32%), with a median response duration of at least 5 months.

    • Conclusions:

    • The sequential chemoimmunotherapy regimen demonstrated notable efficacy in metastatic melanoma.
    • Further investigation into immunologic alterations and toxicity is warranted.